Recently, monitoring data from the World Health Organization showed that the intensity of the new coronavirus activity in Europe, the Americas and other regions has increased. As the novel coronavirus continues to mutate, the current novel coronavirus variants KP.2 and KP.1.1 have become dominant in these places.

According to multiple media reports, the number of COVID-19 cases in Australia has surged recently, and is experiencing the eighth wave of COVID-19, which is feared to reach "a peak for the third consecutive year" by Christmas.

WIZ's two reagents, HBA1C assay kits (fluorescent immunochromatography) and the SARS-CoV-2 Antigen Rapid Test (Colloidal gold) (Anterior nasal) have been approved by the Medical Device Authority (MDA) of Malaysia and began market access.

The last week of April is the World Immunization Week, which aims to promote vaccination and protect people of all ages from disease. Vaccination saves countless lives and is recognized as one of the most successful and cost-effective health interventions.

Point-of-care testing (POCT) is the rapid testing of biological samples (such as blood, urine, saliva, breath gas, etc.) at the patient's side, using simple instruments or reagents, and results can be obtained within minutes to hours. The test can help physicians make timely diagnosis and treatment plans, and provide important information to improve treatment outcomes in an emergency setting.

According to relevant data, the global market size of in vitro diagnostics in 2020 is $71.49 billion, and that of 2021 is $92.08 billion, which is expected to grow from $71.43 billion in 2022 to $107.42 billion in 2029, with a compound annual growth rate of 6% during the forecast period. During this period, the COVID-19 pandemic has increased the demand for in vitro diagnostics, and market participants have collectively witnessed a significant increase in sales and revenue from point-of-care tests.

Our company's "Novel Coronavirus Antibody Screening and Shunt Prevention and Control rapid detection system" has been approved by Xiamen Science and Technology Bureau.